CompanyGraph
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.68B, above the global median of $1.15B
- PositionCurrent ratio is 0.95×, lower than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.68BUSDvs all stocks (USD)
Revenue (TTM)
2.71BUSDvs all stocks (USD)
Profit Margin
-16.50%vs Biotechnology peers
Beta
2.01xvs all stocks
52-Week Change
281.11%vs all stocks
Market Capitalization
1.68BUSDvs all stocks (USD)
Enterprise Value
2.67BUSDvs all stocks (USD)
Forward P/E
16.51xvs Biotechnology peers
Price to Sales (TTM)
0.6202xvs Biotechnology peers
Price to Book (MRQ)
3.19xvs Biotechnology peers
Enterprise to Revenue
0.9840xvs Biotechnology peers
Enterprise to EBITDA
38.15xvs Biotechnology peers
Gross Margin
19.42%vs Biotechnology peers
Profit Margin
-16.50%vs Biotechnology peers
Operating Margin
0.52%vs Biotechnology peers
Return on Assets (TTM)
-0.05%vs Biotechnology peers
Return on Equity (TTM)
-64.55%vs Biotechnology peers
Revenue (TTM)
2.71BUSDvs all stocks (USD)
Revenue per Share (TTM)
29.42USDUpdated Jul 18, 2026Quarterly Revenue Growth
-2.30%vs Biotechnology peers
Gross Profit (TTM)
510.90MUSDvs all stocks (USD)
EBITDA (TTM)
84.20MUSDvs all stocks (USD)
Net Income (TTM)
-446.90MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
220.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
285.61MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.72BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
2.22BUSDFY2025 · Dec 31, 2025Gross Profit
503.80MUSDFY2025 · Dec 31, 2025Operating Income
-30.60MUSDvs all stocks (USD)
Pre-tax Income
-983.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.20MUSDFY2025 · Dec 31, 2025Net Income
-986.20MUSDFY2025 · Dec 31, 2025EBIT
-891.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
55.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
456.40MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
91.40MUSDFY2025 · Dec 31, 2025EPS (Basic)
-10.81USDFY2025 · Dec 31, 2025EPS (Diluted)
-10.81USDFY2025 · Dec 31, 2025Basic Shares Outstanding
91.23MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
91.23MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-986.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-774.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
174.60MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-986.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
78.00MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-32.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
74.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
16.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
70.90MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-109.90MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
114.80MUSDFY2025 · Dec 31, 2025Net Acquisitions
39.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
39.60MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
453.90MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-529.60MUSDFY2025 · Dec 31, 2025Other Financing Charges
-600.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-76.30MUSDFY2025 · Dec 31, 2025Shares Outstanding
94.60MSharesUpdated Jul 18, 2026Float Shares
93.71MSharesUpdated Jul 18, 2026Shares Short
9.77MSharesUpdated Jul 18, 2026Short Ratio
6.19daysvs all stocks
Short % of Shares Outstanding
12.14%vs all stocks
% Held by Insiders
1.01%vs all stocks
% Held by Institutions
110.81%vs all stocks
Total Cash (MRQ)
147.50MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.56USDUpdated Jul 18, 2026Total Debt (MRQ)
1.12BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.13xvs Biotechnology peers
Current Ratio (MRQ)
0.9490xvs Biotechnology peers
Book Value per Share (MRQ)
5.56USDUpdated Jul 18, 2026Total Assets
2.72BUSDvs all stocks (USD)
Total Current Assets
897.20MUSDFY2025 · Dec 31, 2025Total Liabilities
2.15BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.82BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.24BUSDFY2025 · Dec 31, 2025Total Current Liabilities
913.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
174.60MUSDFY2025 · Dec 31, 2025Accounts Receivable
113.60MUSDFY2025 · Dec 31, 2025Accounts Payable
29.70MUSDFY2025 · Dec 31, 2025Short-term Debt
14.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
473.80MUSDFY2025 · Dec 31, 2025Other Current Liabilities
28.20MUSDFY2025 · Dec 31, 2025Long-term Debt
1.10BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
39.30MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.38BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
563.50MUSDvs all stocks (USD)
52-Week Low
4.57USDUpdated Jul 18, 202652-Week High
18.67USDUpdated Jul 18, 202652-Week Change
281.11%vs all stocks
Beta
2.01xvs all stocks
50-Day MA
15.95USDUpdated Jul 18, 2026200-Day MA
13.11USDUpdated Jul 18, 2026Avg 10-Day Volume
993.87KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.40MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-4.81USDUpdated Jul 18, 2026Other Income / Expense
-861.00MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.95×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.95Industry median: 5.50Industry P5: 0.97Peers compared: 197
Structural Tensions
Most companies in its industry are production businesses; this one is a sense-making businessSignificant
Industry peers: 502Share on the common pattern %: 98.00
Financial Health
Altman Z-Score -0.33: distress zoneCritical
Altman Z-Score: -0.33
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.68B, above the global median of $1.15BNotable
Market cap (USD): 1,679,824,804Global Median: 1,146,734,693.424
Revenue is $2.71B, above the global median of $520.53MNotable
Revenue (USD): 2,708,600,064Global Median: 520,528,949.311
Levered free cash flow is $285.61M, above the global median of $16.24MNotable
Levered free cash flow (USD): 285,612,512Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Evotec SE
Tier 1SenseMakingApproval-Gated PipelineInterfaceProduction
Caris Life Sciences, Inc.
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Ixico plc
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Shanghai Medicilon Inc.
Tier 2SenseMakingApproval-Gated PipelineProduction
Hvivo Plc
Tier 2SenseMakingApproval-Gated PipelineProductionRule
Fusion Antibodies Ltd.
Tier 2SenseMakingApproval-Gated PipelineProduction
Hilan Ltd.
Tier 3SenseMakingExpertise LeverageProductionFlow
Chinasoft International Limited
Tier 3SenseMakingExpertise LeverageProductionFlow
Northking Information Technology Inc.
Tier 3SenseMakingExpertise LeverageFlow
Guangzhou Sie Consulting Co. Ltd.
Tier 3SenseMakingExpertise LeverageFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Ch. Karnchang Public Company Limited
1 interpretationWithin or Near the Altman Distress Zone
Shandong Longda Meishi Co., Ltd.
1 interpretationWithin or Near the Altman Distress Zone
China High-Speed Railway Co., Ltd.
1 interpretationWithin or Near the Altman Distress Zone